X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4442) 4442
Publication (406) 406
Newspaper Article (316) 316
Report (105) 105
Book Review (83) 83
Book Chapter (69) 69
Web Resource (55) 55
Trade Publication Article (41) 41
Magazine Article (8) 8
Conference Proceeding (5) 5
Book / eBook (4) 4
Dissertation (3) 3
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3511) 3511
index medicus (2472) 2472
initial treatment (1853) 1853
male (1750) 1750
female (1736) 1736
middle aged (1365) 1365
adult (1247) 1247
treatment outcome (1104) 1104
aged (972) 972
oncology (728) 728
drug therapy, combination (704) 704
gastroenterology & hepatology (643) 643
care and treatment (599) 599
hepatitis c, chronic - drug therapy (582) 582
antiviral agents - therapeutic use (551) 551
initial public offerings (537) 537
initial-experience (519) 519
infectious diseases (503) 503
pharmacology & pharmacy (495) 495
therapy (492) 492
cancer (487) 487
double-blind (476) 476
initial therapy (472) 472
recombinant proteins (449) 449
medicine & public health (441) 441
interferon-alpha - therapeutic use (424) 424
randomized-trial (419) 419
ribavirin - therapeutic use (415) 415
combination therapy (412) 412
hematology (409) 409
hepatitis c (390) 390
analysis (384) 384
ribavirin (383) 383
retrospective studies (381) 381
radiology, nuclear medicine & medical imaging (365) 365
clinical trials (362) 362
research (356) 356
drug therapy (353) 353
surgery (353) 353
combination (350) 350
risk factors (348) 348
aged, 80 and over (341) 341
health aspects (337) 337
adolescent (333) 333
plus ribavirin (332) 332
interferon (296) 296
hepacivirus - genetics (295) 295
hiv infections - drug therapy (295) 295
prognosis (295) 295
virology (287) 287
genotype (286) 286
medicine, general & internal (286) 286
follow-up studies (281) 281
infection (280) 280
animals (279) 279
chemotherapy (272) 272
prospective studies (271) 271
patients (269) 269
interferon-alpha-2b plus ribavirin (265) 265
efficacy (262) 262
peginterferon alpha-2a (255) 255
virus-infection (254) 254
antineoplastic combined chemotherapy protocols - therapeutic use (253) 253
diagnosis (249) 249
viral load (249) 249
time factors (245) 245
antiviral agents - administration & dosage (240) 240
young adult (234) 234
interferon-alpha - administration & dosage (225) 225
ribavirin - administration & dosage (220) 220
child (218) 218
immunology (218) 218
internal medicine (217) 217
management (215) 215
trial (215) 215
abridged index medicus (212) 212
survival (212) 212
polyethylene glycols - therapeutic use (207) 207
hepatitis c, chronic - virology (203) 203
hepatitis c virus (202) 202
hiv (202) 202
antiviral agents - adverse effects (199) 199
usage (195) 195
follow-up (193) 193
article (190) 190
rna, viral - blood (187) 187
safety (185) 185
drug administration schedule (184) 184
randomized controlled trials as topic (184) 184
medical research (181) 181
mortality (180) 180
open-label (174) 174
rituximab (174) 174
hepatitis c - drug therapy (173) 173
hepacivirus - drug effects (172) 172
initial combination therapy (170) 170
cardiac & cardiovascular systems (168) 168
clinical neurology (167) 167
interferon-alpha - adverse effects (166) 166
pharmaceutical industry (165) 165
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (2) 2
Robarts - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4944) 4944
German (38) 38
French (36) 36
Japanese (13) 13
Spanish (13) 13
Russian (6) 6
Croatian (1) 1
Italian (1) 1
Polish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2/2009, Volume 48, Issue 3, pp. 350 - 361
Journal Article
Leukemia, ISSN 0887-6924, 04/2018, Volume 32, Issue 4, pp. 920 - 930
Acalabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, is associated with high overall response rates and durable remission in previously... 
APOPTOSIS | BRUTONS TYROSINE KINASE | ONCOLOGY | IN-VIVO | BONE-MARROW | INITIAL THERAPY | B-CELL MALIGNANCIES | CHRONIC LYMPHOCYTIC-LEUKEMIA | OPEN-LABEL | INHIBITOR | HEMATOLOGY | EXPRESSION | Protein-Tyrosine Kinases - metabolism | Humans | Pyrazines - administration & dosage | Benzamides - administration & dosage | Chemokine CCL3 - metabolism | Chemokine CCL4 - metabolism | B-Lymphocytes - metabolism | Pyrimidines - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | B-Lymphocytes - drug effects | Cell Movement - drug effects | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Animals | Adoptive Transfer - methods | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Proteomics | Combined Modality Therapy - methods | Mice | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Clinical Trials, Phase I as Topic | Sulfonamides - administration & dosage | Clinical Trials, Phase II as Topic | Drug Resistance, Neoplasm - drug effects | Chronic lymphocytic leukemia | Pharmacology, Experimental | Oncology, Experimental | Development and progression | Pharmacology | Research | Drug therapy, Combination | Drug therapy | Cancer | Therapy | Leukocyte migration | Leukemia | Carbon tetrachloride | Clinical trials | Immunoblotting | B-cell receptor | Kinases | Adoptive transfer | Cell adhesion & migration | Proteins | Signal transduction | Lymphocytes | Peripheral blood | Remission | Protein-tyrosine kinase | Tyrosine | Medical research | Pharmacodynamics | Chronic lymphatic leukemia | Cell survival | CCL3 protein | Lymphatic leukemia | CCL4 protein | Patients | Bruton's tyrosine kinase | Signaling | Protein arrays | Lymphocytes B | Chemokines | Combinatorial analysis | Cell migration | chronic lymphocytic leukemia | Acalabrutinib | venetoclax | BTK inhibitor
Journal Article
Journal Article
Pediatrics, ISSN 0031-4005, 01/2012, Volume 129, Issue 1, pp. e17 - e23
Journal Article
ANNALS OF INTERNAL MEDICINE, ISSN 0003-4819, 03/2004, Volume 140, Issue 5, pp. 346 - 355
Background: Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in... 
ALPHA-2A | TRIAL | MEDICINE, GENERAL & INTERNAL | VIRUS | EFFICACY | PHARMACOKINETICS | SAFETY | INTERFERON-ALPHA-2B PLUS RIBAVIRIN | INITIAL TREATMENT | INFECTION | PEGYLATED INTERFERON-ALPHA-2B
Journal Article
GASTROENTEROLOGY, ISSN 0016-5085, 10/2002, Volume 123, Issue 4, pp. 1061 - 1069
Background & Aims: Patient adherence to prescribed antiviral therapy in human immunodeficiency virus infection enhances response. We evaluated the impact of... 
HCV RNA | VIRUS | ALPHA THERAPY | INTERFERON-ALPHA-2B PLUS RIBAVIRIN | INITIAL TREATMENT | INFECTION | GASTROENTEROLOGY & HEPATOLOGY | RANDOMIZED TRIAL
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2014, Volume 9, Issue 3, p. e90295
Objective: To explore the expected long-term health and economic outcomes of telaprevir (TVR) plus peginterferon alfa-2a and ribavirin (PR), a regimen that... 
SUSTAINED VIROLOGICAL RESPONSE | UNITED-STATES | INTERFERON-ALPHA-2B | VIRUS-INFECTION | MULTIDISCIPLINARY SCIENCES | LIVER FIBROSIS | DISEASE | INITIAL TREATMENT | FOLLOW-UP | ALPHA-2B PLUS RIBAVIRIN | PEGINTERFERON | Recombinant Proteins - therapeutic use | Follow-Up Studies | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | Fatigue - chemically induced | Models, Economic | Recombinant Proteins - adverse effects | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Clinical Trials, Phase III as Topic | Multicenter Studies as Topic | Female | Hepacivirus - drug effects | Quality-Adjusted Life Years | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Anemia - chemically induced | Genotype | Drug Therapy, Combination - economics | Hepatitis C, Chronic - drug therapy | Randomized Controlled Trials as Topic | Outcome Assessment (Health Care) - economics | Ribavirin - adverse effects | Cost-Benefit Analysis | Interferon-alpha - adverse effects | Medical research | Liver | Economic aspects | Medicine, Experimental | Biological products industry | Interferon | Comparative analysis | Hepatitis C virus | Medical economics | Health aspects | Viral antigens | Transition probabilities | Costs | Medical services | Clinical trials | Viruses | Markov chains | Infections | Ribavirin | Subgroups | Hepatitis | Liver cancer | Genotype & phenotype | Genotypes | Sensitivity analysis | Liver diseases | Complications | Mortality | Medical treatment | Decision analysis | Patients | Pharmacoeconomics | Adults | Hepatitis C | Cost analysis
Journal Article